Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations

- October 29th, 2020

Bausch Health Companies Inc. today announced that on Nov. 30, 2020 it will redeem approximately $100 million aggregate principal amount of its outstanding 5.875% Senior Notes due 2023, CUSIP Nos. 91831A AB7, C96729 AB1 , representing the entire outstanding amount of the 5.875% Notes and approximately $50 million aggregate principal amount of its outstanding 5.50% Senior Notes due 2023, CUSIP Nos. 91911K AE2, C94143 …

– Bausch Health Companies Inc. (NYSETSX: BHC) (“Bausch Health” or the “Company”) today announced that on Nov. 30, 2020 it will redeem (i) approximately $100 million aggregate principal amount of its outstanding 5.875% Senior Notes due 2023, CUSIP Nos. 91831A AB7, C96729 AB1 (the “5.875% Notes”), representing the entire outstanding amount of the 5.875% Notes and (ii) approximately $50 million aggregate principal amount of its outstanding 5.50% Senior Notes due 2023, CUSIP Nos. 91911K AE2, C94143 AE1 (the “5.50% Notes” and, together with the 5.875% Notes, the “Notes”), using cash generated from operations.

The Company will issue today irrevocable notices of redemption for each series of Notes and a copy will be issued to the record holders of such Notes. Nothing contained herein shall constitute a notice of redemption of the Notes. Payment of the redemption price and surrender of the Notes for redemption will be made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust Company. The name and address of the U.S. paying agent are as follows: The Bank of New York Mellon Trust Company, N.A., c/o The Bank of New York Mellon; 111 Sanders Creek Parkway, East Syracuse, N.Y. 13057; Attn: Redemption Unit; Tel: 800-254-2826.

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com .

Caution Regarding Forward-Looking Information and “Safe Harbor” Statement
This news release may contain forward-looking statements, including, but not limited to, the redemption of the Notes. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company’s most recent annual and quarterly reports and detailed from time to time in the Company’s other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Investor Contact:

Media Contact:

Arthur Shannon

Lainie Keller

arthur.shannon@bauschhealth.com

lainie.keller@bauschhealth.com

(514) 856-3855

(908) 927-1198

(877) 281-6642 (toll free)

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/bausch-health-to-reduce-debt-by-150-million-using-cash-generated-from-operations-301161829.html

SOURCE Bausch Health Companies Inc.

News Provided by PR Newswire via QuoteMedia

  Life Science and Healthcare Investing in 2020 report cover

Life Science and Healthcare Investing in 2020

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2020 life science outlook report!
 

Leave a Reply